Aclaris Eyes Breakout on Upcoming Clinical Results
AI Prediction of Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, shows potential for significant stock price movement due to its focused development on novel drug candidates for immuno-inflammatory diseases. The recent inclusion in the Russell 2000 and 3000 indexes, alongside promising clinical trial advancements for its key drug candidates, positions ACRS as a potentially attractive investment opportunity.
ACRS Report Information
Prediction Date2025-07-03
Close @ Prediction$1.44
Mkt Cap488m
IPO Date2015-10-07
AI-derived Information
Recent News for ACRS
- Jan 27 — Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug (Benzinga)
- Jan 27 — Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) (GlobeNewswire)
- Jan 13 — Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 (TipRanks)
- Jan 12 — Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 (GlobeNewswire)
- Jan 6 — Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development (GlobeNewswire)
- Dec 19 — Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) (GlobeNewswire)
- Nov 25 — Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
- Nov 6 — Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
- Nov 6 — Aclaris: Q3 Earnings Snapshot (Associated Press Finance)
- Nov 6 — Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.